1. The numbers of CGN patients have decreased, with a corresponding increase in transplants into
IDDM. HTN and
MHT have also increased in recent years. 2. Waiting time on dialysis has increased, with an increase in patient age. 3. Transfusions have decreased for all diseases, although less so for SLE. 4. Disease recurrence was highest in FGS,
IgA, SLE and CGN. The incidence of recurrence has decreased in recent years. 5.
Tacrolimus-MMF and
Neoral-MMF were superior to CsA-AZ for all diseases with respect to 5-year graft survival. 6. Systemic diseases such as SLE and
IDDM had lower graft survival rates than
IgA, PC and ALP. Exclusion of deaths made functional graft survival of all diseases quite similar. 7. Blacks had lower graft survival rates than Whites, Hispanics, and Asians for all diseases. 8. SPK had higher graft survivals than KA in Blacks and Whites. 9. PC patients with
HLA-DR1 had a statistically significant higher graft survival than those without DR1 in Whites and Hispanics. 10.
IDDM patients with
HLA-DR4 had a statistically significantly higher graft survival rates than those without DR4 in Blacks, Whites, Hispanics, and Asians. 11. PC,
IgA, and ALP patients had a lower incidence of rejection before discharge than other patients. HTN and
IDDM patients had the highest rate of first day non-function and need for dialysis. 12. Need for dialysis and rejection before discharge led to 20 percentage points lower 5-year graft survival compared with those patients who were free of these complications. 13. First day
anuria led to 10 percentage point lower 5-year graft survival compared with those with first day diuresis.